Wong WM et al. |
Standard treatment for Helicobacter pylori infection is suboptimal in non-ulcer dyspepsia compared with duodenal ulcer in Chinese. |
2005 |
Aliment. Pharmacol. Ther. |
pmid:15644048
|
Wong WM et al. |
Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12622764
|
Fischbach L and Evans EL |
Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. |
2007 |
Aliment. Pharmacol. Ther. |
pmid:17635369
|
Logan RP et al. |
Eradication of Helicobacter pylori and prevention of recurrence of duodenal ulcer: a randomized, double-blind, multi-centre trial of omeprazole with or without clarithromycin. |
1995 |
Aliment. Pharmacol. Ther. |
pmid:8527618
|
Masaoka T et al. |
Second-line treatment of Helicobacter pylori infection after dilution agar methods and PCR-RFLP analysis. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15298608
|
Kondo Y et al. |
Helicobacter pylori eradication decreases blood neutrophil and monocyte counts. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15298609
|
Gschwantler M et al. |
Famotidine versus omeprazole in combination with clarithromycin and metronidazole for eradication of Helicobacter pylori--a randomized, controlled trial. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10468682
|
Chiba N et al. |
Economic evaluation of Helicobacter pylori eradication in the CADET-Hp randomized controlled trial of H. pylori-positive primary care patients with uninvestigated dyspepsia. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:14984382
|
Di Mario F et al. |
Bovine lactoferrin for Helicobacter pylori eradication: an open, randomized, multicentre study. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:16611285
|
Madisch A et al. |
Healing of lymphocytic gastritis after Helicobacter pylori eradication therapy--a randomized, double-blind, placebo-controlled multicentre trial. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:16441467
|
Molina-Infante J et al. |
Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study. |
2015 |
Aliment. Pharmacol. Ther. |
pmid:25776067
|
Azuma T et al. |
Pharmacokinetics of clarithromycin in Helicobacter pylori eradication therapy in patients with liver cirrhosis. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10807427
|
Talley NJ et al. |
Nizatidine in combination with amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9678811
|
Shokri-Shirvani J et al. |
Letter: global emergence of Helicobacter pylori antibiotic resistance - unanswered questions. |
2016 |
Aliment. Pharmacol. Ther. |
pmid:27137738
|
Kashimura H et al. |
Polaprezinc, a mucosal protective agent, in combination with lansoprazole, amoxycillin and clarithromycin increases the cure rate of Helicobacter pylori infection. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10215732
|
Vcev A et al. |
Pantoprazole, amoxycillin and either azithromycin or clarithromycin for eradication of Helicobacter pylori in duodenal ulcer. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10632647
|
Laine L et al. |
A United States multicentre trial of dual and proton pump inhibitor-based triple therapies for Helicobacter pylori. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9354200
|
Gisbert JP et al. |
Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures. |
2012 |
Aliment. Pharmacol. Ther. |
pmid:22372560
|
Harris AW et al. |
Lansoprazole, clarithromycin and metronidazole for seven days in Helicobacter pylori infection. |
1996 |
Aliment. Pharmacol. Ther. |
pmid:8971302
|
Graham DY et al. |
Meta-analysis: proton pump inhibitor or H2-receptor antagonist for Helicobacter pylori eradication. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12755836
|